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Chapter I. Introduction and Review ofthe Literature
Immune systems respond to the presenceof diseased cells, foreign
matter and infectious organismsby a directed response that begins with the
introduction of an antigen.1 An antigen is amacromolecule that induces the
formation of immunoglobulins (antibodies)and/or sensitized cells which
react specifically with the antigen.The antigen may also be a cell which
contains ligands (called epitopes) or smallclusters of molecules on its surface
that are not present on cells of thehost organism. A more descriptive
illustration is not possible since antigens aredefined by the antibodies they
produce and antibodies are defined by theantigens that produce them.2
Immune systems also vary intheirlevelsofsophistication.
Invertebrates (and some vertebrates) relyonly on phagocytic cells that have
general receptors for any foreign intruder. Mostvertebrates have, in addition
to such phagocytic cells, immunesystems that can adapt to combatinfectious
organisms. In the adaptive immune system,cells can detect the presence of
antigens via receptors which bind to specificepitopes of the antigen.
Innate immune systems primarily useneutrophils, eosinophils, and
basophils which contain granularcytoplasm.In addition to these
polymorphonuclear cells, innate systems utilizewhite blood cells (called
monocytes) and other cells which arederived from monocytes (called
macrophages).Of these immune cells, monocytes,macrophages, and
neutrophils are the most active.
In adaptive immune systems two typesof cells are the most important:
B lymphocytes (B cells) and T lymphocytes(T cells). Both cell types originate2
in bone marrow, but B cells mature in the bursa of Fabricus (birds) and Tcells
in the thymus. Mammals do not have a bursa of Fabricus and it is believed,
although not certain, that gut-associated lymphoid tissue (GALT) is the
mammalian equivalent.Both cell types exhibit similar morphology, but
differ in many respects. The most important functional differences are that B
cells are primarily associated with antibody production while T cells are
primarily associated with directing the host's immune response.
The surface of B cells contain large numbers of specific receptors, and
proliferation of B cells occurs when an antigen binds to a specific B cell. This
causes the cell to multiply (along with othersignals such as those induced by
T helper cells) in a process known as clonal expansion. Some of these new
cells (called plasma cells) are immunoglobulin (antibody) synthesizing cells.
These antibodies can bind to specific epitopes in the antigen, either when the
antibody is on the surface of the B cell, or when the antibody is excreted by the
plasma cell.Occasionally, some of the B cells differentiate into "memory"
cells that can remain in the body long after an infection has been repulsed.
This is one reason why people who recover from most diseases are not likely
to acquire them again.3High concentrations of B cells are found in the
spleen, but B cells exhibit low blood concentrations.
The T cells are differentiated into several subsets with each subset
regulating a different immune response.4 Cytotoxic T cells (Tc cells) kill the
host's cells when they become infected, and suppresser T cells (Ts cells)
prevent the activation of other immune cells.Helper T cells (Th cells)
produce and secrete molecules that activate B cells which regulate thehost's
responses.The secreted molecules are called lymphokines andinclude3
interleukins 2,3,4 (I1-2, 11 -3, 11-4) and y-interferon. Unlike B cells, T cells have
relatively high blood concentrations and concentrate in thoracic lymph
nodes.
Another difference exhibited between T cells and B cells is the mode of
antigen recognition.5 T cells, unlike B cells, do not bind independently with
an antigen.The T cell receptor (TCR) must bind simultaneously to the
antigen and a specific cluster of molecules called the major histocompatibility
complex (MHC) that occurs on the surface of the host's cells. This permits T
cells to identify infected cells and interact only with immune cells of the same
antigen receptor. The host is thus able to mount an immune response
against infected tissues only.
This mode of action has significant consequences with respect to organ
and tissue in the role of T cells in transplant rejection. Such rejection usually
occurs when tissues are transplanted between people with markedlydifferent
genes in the MHC region.The MHC region in these transplanted cells
present foreign epitopes to Tc and Th cells leading to the host's immune
system responding to irradicate the foreign cells. Graft rejection occurs when
antibodies form in response to surface MHC molecules of the transplanted
organ. If this process proceeds unimpeded, the host's immune responsewill
ultimately lead to cellular death and organ rejection.Prior to the
introduction of immunosuppressive compounds, only grafts from closely
matched siblings or highly inbred animal strains avoided rejection by the
host.With the use of selective immunosuppressive compounds, more
general methods of host-graft transplantation have become available.6,7
It has been known for decades that certain compounds, such as 6-
mercaptopurine, suppress the body's ability to mount an immuneresponse.8
Chief among today's therapeutic immunosuppressants is the macrocyclic4
peptide cyclosporin A (1) (CsA). CsA, a fungal metabolite of Tolypocladium ,
was first isolated in 1971.9 The N-methylbutenylthreonine moiety(attached
to C-1) was unknown before the elucidation of CsA's structure. CsA is in fact
routinely used in heart, liver, kidney and lung transplants and has led to a
high success rate for transplantation in humans. It has become the drug of
choice to prevent organ rejection and has significantly increased long-term
survival rates of individuals who have received these transplants.
HO
Me e Me M
.r.Me 0,NC NC Nc yCN. )2..C'
1 0 P 0 H0 I
' , ,i 9=0
,
MeN NH ,
1 0 H O H
C
I I I I I,
0-,.,.- NC --FN CN C N--.'s
Me H Me9 Me N°
11
I I
1
CsA is a strong immunosuppressant that is absorbed by T cells during
the initial stages of mitosis and selectively prohibits T cell proliferation.
Interference by CsA with Th cells inhibits production of interleukins and y-
interferon.10 One of the more undesirable side effects of CsA is its potential
for kidney damage, leading to kidney failure in extreme cases.115
FK506 (2), another promising immunosuppressive agent, was isolated
from the bacteria Streptomyces tsukukaenis in 1987.12 This 23-membered
macrolide was also found to be immunosuppressive with bioactivity similar
to CsA, and is currently undergoing clinical trials for use in humans.13
Importantly, FK506 has been shown to be 10-100 times more effective than
CsA. However, in relatively high concentrations FK506 has been shown to be
toxic in animals.This undesirable trait is circumvented by the lower
concentrations required for therapeutic efficacy.
Recently it was discovered that discodermolide (3) and deoxyspergualin
(4)also show immunosuppressive activity.13 Presently, work is under way to
determine the signaling mechanisms by which these compounds operate, but
it is not yet known by what mechanism they inhibit T cell activation.13H H2N.N
NH
3
4
NH(CH2)4NH(CH2)3NH2
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Rapamycin (5) is a metabolite of Streptomyces hygroscopicusand was
isolated in 1975.14Although it was first described as a potent antibiotic,
subsequent studies have shown it also affects the histologyof lymphoid
tissues. Rapamycinwaslaterdiscoveredtobeapowerful
immunosuppressant as wel1.15a-cAlthough CsA (1) and FK506 (2) both
inhibit the production of interleukins and y-interferon,rapamycin does not.
Instead, rapamycin inhibits the response ofimmune cellstothese
lymphokines13,16 and is effective at concentrations similar to those associated
with FK506. When used jointly, rapamycin and FK506inhibit each other's
activity. However, when FK506 is administeredsimultaneously with CsA an
increase in effectiveness has been observed.Rapamycin has recently been
used successfully in animal models to suppress graftrejection, 17,18 and like
FK506, rapamycin can also exhibit adverse side effects athigh dosage levels.18
Rapamycin inhibits T and B cell proliferation at alater stage in the immune
response than does FK506 and canoperate on immune response pathways7
insensitive to FK506 such as I1-2 mediated T cell response.It inhibits
activationof Tcellsbyphorbolesterand Bcellsbybacterial
lipopolysaccharide.19
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Much effort has been directed to the synthesis of rapamycin (5) and the
structurally similar FK506 (2) due to their potent activity20a-k,21a4and in
particular to the construction of the "tricarbonyl" moiety of both these two
macrolides.22a-m The tricarbonyl region (C8-C10) has been shown to be crucial
to the immunosuppressive activity of rapamycin.23All current synthetic
studiesculminate in an oxidation step at or near the final stages of the
synthesis, for which the oxidative methods employed varied considerably.
One of the earliest studies22a by Kocienski and co-workers made use of the 13-
ketoamide 7 obtained from the a-diazo-13-hydroxyamide 6 (Scheme I). The
amide 7 was treated with dimethylformamide dimethylacetal, giving the
desired enamine 8, and ozonolysis of 8 afforded the desired tricarbonyl8
intermediate.Desilylation followed by formation of thelactal was
accomplished by in situ reaction with hydrofluoric acid to furnish the FK506
tricarbonyl segment 9.
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Rao and co-workers22b synthesized the tricarbonyl subunit of FK506 by
ozonolysis of a similar enamine intermediate in the final step (Scheme II).
This synthesis began with the previously described24methyl 4,6-0-
benzylidene-2-deoxy-2-methyl-a-D-glucopyranoside(10)obtainedfrom
methyl a-D-glucopyranoside.The C-3 hydroxy group was removed by
reduction of the xanthate with tri-n -butyltin hydride. The benzylidene acetal
was readily cleaved with acid and the product was treated with trityl chloride9
to protect the primary alcohol. Methylation of the secondary alcohol at C-4
gave the ether 11. This pyranoside was ring-opened and the trityl group was
removed with acid in the presence of 1,3-propanedithiol to give the thioacetal
12.The diol moiety of 12 was converted to the acetonide 13 with 2,2-
dimethoxypropane in the presence of an acid catalyst, and when 13 was
treated with n-butyllithium and then with methyl N-bromoacetylpipecolate
(14) the ester 15 was obtained. The enamine 16 was prepared by converting
thethioacetaltoaketone,reactingtheresultant13-diketonewith
dimethylformamide dimethylacetal, and hydrolyzing the acetonide to give 16
in low overall yield. The final step was accomplished by ozonolysis of 16
which gave the FK506 tricarbonyl subunit 17.
In their approach to the tricarbonyl subunit of FK506, Williams and co-
workers22c used selenium dioxide to oxidize a 0-ketoamide precursor as
shown in Scheme IR.The aldehyde 1825 was reacted with the freshly
prepared Grignard reagent 19 derived from methyl (R )-(-)-3-hydroxy-2-
methylpropionate26 to give 20 as the major stereoisomer. The secondary
alcohol of 20 was first methylated, and this was followed by a dissolving
metal deavage of the benzyl ether to yield the primary alcohol 21 as a single
isomer after column chromatography.Oxidation of 21 with Jones' reagent
gave the carboxylic acid 22 without ketal hydrolysis, and conversion tothe
acid chloride 23 was accomplished by addition of excess oxalyl chloride to 22.
The pipecolic amide 24 was converted to its magnesium enolate with
isopropylmagnesium chloride, and then 23 was added dropwise to give the
acylated product 25 as a mixture of enolic isomers.Hydrogenolysis and
decarboxylation of 25 resulted in the formation of the 0-ketoamide. The
carboxylic acid resulting from hydrogenolysis of the benzyl pipecolate was
reprotected as methyl ester 26 by treatment with diazomethane. Oxidation of13 OMe
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this f3- ketoamide with selenium dioxide in refluxing dioxane gave the
tricarbonyl precursor 27 as a partial hydrate (33% hydrated). Conversion of 27
to the FK506 subunit 17 was accomplished by ketal hydrolysis with
hydrochloric acid in methanol.
Synthetic strategies directed toward the FK506 tricarbonyl subunit have
been the focus of much research in the Danishefsky grOup.22d,e Their first
approach began with the conversion of the easily preparedtert-butyl
pipecolate 28 into the oxalyl derivative 29 by treatment with methyloxalyl
chloride (Scheme IV).
Treatment of thioacetal 30 with n - butyllithium followed by addition of
the electrophile 29 gave the f3-thioketal adduct, which was reacted with
hydrogen fluoride in acetonitrile to give the alcohol 31.Exposure of the
thioketal to N-bromosuccinimide in acetone gave the diketoamide which
cydized spontaneously to the masked FK506 tricarbonyl subunit 32.
A different strategy22e by the Danishefsky group focused on the use of
Dess-Martin periodinane for the oxidation of model systems similar to those
found in rapamycin and FK506 (Scheme V). The enolate of racemic 33 reacted
with benzaldehyde to give the alcohol 34 as a mixture of diastereoisomers
which was oxidized with the Dess-Martin reagent to afford the tricarbonyl
compound 35. This approach was extended by coupling 33 with the racemic
aldehyde 36, giving the alcohol 37 as a mixture of diastereoisomers.
Treatment of 37 with the Dess-Martin periodinane yielded the pipecolate 38.
Conversion to 39, a structural unit common to both rapamycin and FK506,
was accomplished by cleavage of the silyl ether, which was followed by
spontaneous cyclization to give the desired hemiketal.Et20, -78°C,
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Wasserman and co-workers22f also utilized an ozonolysis to produce
the tricarbonyl moiety of FK506 (Scheme VI). The N-bromoacetyl derivative
40, prepared from the t-butyl ester of (-)-pipecolinic acid, was treated with
triphenylphosphine to give a phosphonium salt, from which the ylide 41 was
obtained by treatment with dilute sodium hydroxide. The ylide reacted with
the acid chloride 23220 in the presence of bis(trimethylsilyl)acetamide to give
the keto ylide 42 which was ozonized to give a tricarbonyl compound.
Quantitative hydrolysis of the ketal and cyclization to the FK506 tricarbonyl
subunit 43 was accomplished with dilute hydrochloric acid in methanol.
The Hoffman group22g carried out a model study on tricarbonyl
systems similar to those found in rapamycin and FK506 in which a two-step
oxidation of a I3-keto amide 46 was used (Scheme VII).0-keto amides 46 were
prepared from the corresponding 3 -keto esters 44 and a secondary amine 45 in
the presence of 4-dimethylaminopyridine in refluxing toluene. The yields of
the 13-keto amides were low, ranging from 14% to 46%. These 13-keto amides
were readily converted to the 2-(nosyloxy)-3-keto amides 47by treatment with
p-nitrobenzenesulfonyl peroxide and zinc chloride. Reaction of 47 with 1,8-
diazobicyclo[5.4.0]undec-7-ene gave the crude tricarbonyl compound 48. Since
this compound could be purified, the crude mixture was treated with o-
phenylenediamine in order to trap the tricarbonyl compound asits
quinoxalinederivative 49.
A similar study by Golec and co-workers22h also made use of 13-keto
amides as well as fl-hydroxy amides for the preparation of model tricarbonyl
systems.In their work, Dess-Martin periodinane was used to obtain the
tricarbonyl compound (Scheme Thus, 13-hydroxy amides 50 and 52 were17
oxidized with Dess-Martin reagent to give tricarbonyl compounds 51 and 53
respectively. When the (3-keto amides 54 and 55 were oxidized under the
same conditions, the tricarbonyl products 51 and 56 wereproduced.
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In a quite different approach, Pattenden and co-workers22i utilized a
catalytic ruthenium dioxide oxidation of an acetylenic amide to furnish the
tricarbonyl portion of rapamycin 67 (Scheme IX).The synthesis began with
the iodide 5727, which was treated with sodium borohydride and tributyltin
hydride to initiate addition of the radical from 57 to methyl acrylate.The
resultant ester 58 was converted to the corresponding aldehyde 59 by initial
reduction to the alcohol with diisobutylaluminum hydride followed by
oxidation with pyridinium chlorochromate and sodium acetate.Wittig20
olefination of 59 gave the dibromide 60 which was converted to the terminal
acetylene 61 with n -butyllithium. The acetonide of 61 was hydrolyzed and
the resultingdiol was protected as the bis(t- butyldimethylsilyl) ether 62.
Metallation of 62 followed by reaction with carbon dioxide gave the carboxylic
acid 63.Coupling of the piperidine 64 with 63 using benzotriazol-1-
yloxytris(dimethylamino)phosphoniumhexafluorophosphategavethe
acetylenic amide 65. Oxidation with a ruthenium dioxide sodium periodate
mixture afforded the tricarbonyl system 66 in low yield.Quantitative
deprotection with hydrogen fluoride in acetonitrile gave the tricarbonyl
portion of rapamycin 67 as a 1:1 mixture of diastereoisomers which were
cleanly separated by silica gel column chromatography.
The Rao22i group also used Dess-Martin periodinane to effect oxidation
to the rapamycin tricarbonyl subunit 83 near the end of their synthetic route.
Their synthesis also utilized a double elimination following the coupling of
the epoxy chloride 73 with the (R)-4-bromo-2-methylbutanolsily1 ether 72 to
give the acetylenic compound 74.Two Sharpless epoxidations were
employed in the formation of 69 and 76 to impart the desired stereochemistry
in the final product.
The Rao synthesis began with the Sharpless asymmetric epoxidation of
alcohol 68 with (+)-diethyl tartrate as the chiral auxiliary to give 69 in 95% ee
(SchemeX). Theepoxidewasregioselectivelyopenedwith
trimethylaluminum to yield diol 70.Periodate cleavage of 70 followed by
treatment with sodium borohydride gave the terminalalcohol, and
subsequent protection with t-butyldiphenylsilyl chloride in the presence of
imidazole resulted in the silyl ether. The benzyl ether was cleaved by catalytic21
hydrogenolysis to give the alcohol 71, and the alcohol was converted to the
corresponding bromide 72 by formation of the mesylate followed by
displacement with lithium bromide.
The chloroepoxide 73 was treated with lithium amide and then
coupled with 72 to give the acetylene 74 (Scheme XI).The latter was
hydrogenated to the cis olefin 75 over Lindlar'scatalyst.Sharp less
epoxidation of 75 gave the epoxy alcohol 76 (in 85% ee) which was reduced
regioselectively to afford the diol 77.Desilylation of 77 was followed by
protection of the diol to furnish the acetonide 78, which upon Swern
oxidation yielded the aldehyde 79. Conversion of 79 to a 13-hydroxy ester was
accomplished by a Reformatsky reaction with zinc and ethyl bromoacetate
which gave the ester as a 1:1 mixture of diastereomers. Hydrolysis of the ester
provided the corresponding acid 80 which was coupled with (S)-methyl
pipecolate 81 by first activating the acid as its pentafluorophenyl ester.
Treatment of the amide resulting from coupling 81 to this ester with Dess-
Martin periodinane in situ gave the tricarbonyl compound 82. Hydrolysis of
this material furnished the desired rapamycin tricarbonyl subunit 83.
Mikami and co-workers22k prepared the C10-C15 segment 89 of
rapamycin through an asymmetric carbonyl-ene reaction involving the (S)-
birtaphthol-titanium chiral complex 86 as catalyst (Scheme )GI). The synthesis
began with the previously prepared28 homoallylic ether (R)-84, which when
combined with the glyoxylate 85 in the presence of 10 mole % of (S)-86
afforded hydroxy ester 87 with 97:3 diastereoselectivity. The exo methylene
group was converted to the corresponding ketone 88 viaozonolysis, and the
tosylhydrazone of 88 was reduced with catecholborane to give the C10-C15
rapamycin segment 89 after treatment with sodium acetate.H
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White and Jeffrey221 made use of a Chan rearrangement29 and
oxidation with m -chloroperbenzoic acid in the later stage of their synthesis of
the C8-C19 tricarbonyl segment of rapamycin (Scheme XLII). The synthesis
started from D-(+)-xylose(90)which was converted to its acetonide 91 and the
primary alcohol then protected as its pivalate.The remaining secondary
alcohol was removed by conversion to its xanthate 92 followed by reduction
of the xanthate with tri-n-butyltin hydride. Hydrolysis of the resulting acetal
derivative in the presence of excess ethanthiol gave the thioacetal 93.This
was converted to the aldehyde 94 by first protecting the diol functionality as26
its cyclohexylidene derivative and then by simultaneous hydrolysis of both
the ketal and thioacetal in the presence mercurous chloride.
The phosphonium salt 9530 was treated with n -butyllithium, the
primary alcohol was protected in situ as its trimethylsilyl ether and the
silylated phosphorane was then coupled with 94.The trimethylsilyl ether
was immediately removed to give the alcohol 96.The olefin of 96 was
reduced with diimide and the primary alcohol was oxidized with Dess-Martin
periodinane to give the aldehyde 97.Cleavage of the cyclohexylidene
protecting group by acidic methanolysis was accomplished in good yield and
led to the cyclic acetal which was converted to its methyl ether with
diazomethane. The pivalate was reduced to give a primary alcohol which
was oxidized to the aldehyde 98 upon treatment with Dess-Martin
periodinane.This aldehyde was transformed into methyl ketone 99 by
treatment with methyllithium followed by oxidation of the resulting alcohol
with Dess-Martin periodinane. Ketone 99 was condensed with the anion of
triethyl phosphonoacetate to give an a,(3- unsaturated ester which was
reduced with diisobutylaluminum hydride to furnish the alcohol 100. The
methyl acetal of 100 was opened with 1,3-propandithiol in the presence of
boron trifluoride etherate to give the corresponding dithiane. Both alcohol
functionalities were then protected as t-butyldimethylsilyl ethers to give the
bis silyl ether 101.The dithiane of 101 was removed, and the resulting
aldehyde was oxidized to yield the carboxylic acid 102 which was coupled with
methyl bromoacetate to give the a-(acyloxy)acetate 103.The ester 104 was
formed by trapping the ene-diolate of 104 obtained under the conditions of
the Chan rearrangement.Oxidation of 104 gave the 13-keto ester 105 and the
four silyl groups were removed in methanol over acidic resin to produce the
tricarbonyl subunit 106 of rapamycin.90
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Smith and co-workers22m used stannane chemistry along with Dess-
Martin oxidation to produce the tricarbonyl functionality of rapamycin. Their
synthesis began with the known alkene 10731 which underwent ozonolysis,
giving the aldehyde 108 (Scheme XIV).The vinylstannane 110 resulting from
hydrostannylation of the diyne 109 was reacted with 108 to afford alcohol 111
along with its diastereoisomer. The major alcohol 111 was converted to its
methyl ether 112 and the ortho ester moiety of 112 was hydrolyzed, resulting
in a dihydroxy ester which was silylated to give 113. Reduction of 113 with
diisobutylaluminum hydride gave an alcohol which upon Swern oxidation
yielded the aldehyde 114.
Coupling of N-acetyl-L-pipecolinic acid (115) with aldehyde 114 gave
the carboxylic acid which was converted to methyl ester 116.Treatment of
116 with Dess-Martin periodinane produced the tricarbonyl compound 117
after which the silyl ethers were cleaved to yield the hemiketal.The
hemiketal was converted to the silylated ketal 118 and hydrostannylation of
enyne 118 gave the dienyl stannane. Addition of iodine gave the iodide after
which the methyl ester was cleaved with lithium iodide, resulting in the
rapamycin tricarbonyl subunit 119.Me
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Chapter II. Approaches to the Tricarbonyl Subunit
of Rapamycin
The approach which we initially chose to introduce the tricarbonyl
moiety of rapamycin was based on previous work done in the White group
on the total synthesis of boromycin(123).32 During the later stages of the
synthesis of 123, White and co-workers made use of a double Chan
rearrangement29 to contract a 34-membered ring and form the bis a,13-
enediolate 121 from the bis a-acyloxyacetate 120 (Scheme XV).The
deprotected a,(3-enediolate 121 cydized to the heptaol 122 upon treatment
with tetra-n-butylammonium fluoride and then with hydrochloric acid.
Following this precedent it was postulated that a simpler system (e.g.
124) could be converted to the tricarbonyl precursor of rapamycin 127 by
making use of an analogous Chan rearrangement (Scheme XVI).The
resultant a,(3-enediolamide 126 could, in principle, be deprotected and
oxidized to give the desired rapamycin tricarbonyl subunit 127.
An approach along this line was initiated with the conversion of
commerciallyavailableDL-pipecolinicacid(128)tomethylN-
chloroacetylpipecolate (131). Two possible routes from 128 were examined for
this purpose (Scheme XVII). The first path involved treatment of 128 with
chloroacetyl chloride35 to give chloroacetyl pipecolinic acid (129) which was
esterified with diazomethane to yield the N-chloroacetylpipecolate 131. The
second route to 131 was accomplished by esterification of 128 with methanol
and sulfuric acid to give methyl pipecolate 130.By contrast, an attempt to
convert128to130withdiazomethanefailed. MethylN-
chloroacetylpipecolate (131) was generated from 130 byaddition of
chloroacetyl chloride.ROH
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The carboxylic acid required for coupling with 134 was synthesized in
twostepsfromcommerciallyavailablemethyl(S)-3-hydroxy-2-
methylpropionate (132) (Scheme XWII).Thus, 132 in a mixture of
cyclohexane and dichloromethane was treated with 1.5 equivalents of benzyl
trichloroacetimidate and a catalytic amount of triflic acid34,35 to give the 3-
benzyloxy-2-methylpropionate 133.Basic hydrolysis of 133 in methanol
furnished the carboxylic acid 134.NH
M e 02C
0 H CI3CAOCH2Ph
132
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Scheme XVIII
m e02C oBn
133
NaOH, Me0H,
96%
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Coupling of 131 with 134 was effected with potassium carbonate in
refluxing acetone and gave the a-acyloxy amide 135 as a mixture of two
diastereoisomers in excellent yield (Scheme XIX).However, when Chan
rearrangement of 135 was attempted by treatment with two equivalents of
sodiumbis(trimethylsilyl)amidefollowedbyt-butyldimethylsilyl
trifluoromethanesulfonate, an inseparable mixture of many products was
obtained. When other bases, such as lithium diisopropylamide and lithium
bis(trimethylsilyl)amide, or trapping agents such as trimethylsilyl chloride
were used, complete substrate decomposition or multi-component mixtures
were obtained. No trace of the protected a,13-enediolamide 136 could be
found in the mixture.
In response to this disappointing result, a model study designed to
synthesize the piperidine system 140 was investigated (Scheme XX).This
study, which masks the pipecolate ester as a protected alcohol, began by
acetylation of DL-2-piperidinemethanol (137) with chloroacetyl chloride to
give 138.The alcohol was converted to its trimethylsilyl ether 139, but,39
coupling of 139 with isobutanoic acid under the same conditions as used with
135 led only to decomposition of the starting materials.By contrast, N-
chloroacetylpipecolate 132 underwent coupling with isobutanoic acid to give
141 in good yield. Unfortunately, the pipecolinic acid derivative 141 also gave
inseparablemulti-componentmixturesunderChanrearrangement
conditions.29
131
H 02C , OBn
CO2Me "134
CI
K2C 03, acetone,
Reflux, 81%
CO2Me
OBn
1) 2eq.NaN(SiMe3)2
2) TBDMSOTf
C--1,
NCO2Me
OTBDMS 0
TBDMS0.,--.0Bn
Scheme XIX
136C H2C12, rt, 25 min, 58%
N.-0TMS
C).'o
1400
(S)-1 3 2
A-
Me2CHCO2H,
-*-
K2C 03, acetone,
reflux
TMSOTf, Et3N,
51%
.,.....
N-1/4,.0TMS
CI
139
Me2CHCO2H, NCO2Me
K2C 03, acetone, 0
reflux, 67%
Scheme XX
O
141
40
The failure to effect the rearrangement of 135 and 141 to an enediolate
system prompted a search for an alternative method to secure thetricarbonyl
moiety of rapamycin.The preparation of a-diketones by oxidation of
acetylenes has been well studied36a-e and appeared to offer an attractive entry
to the 1,2,3-tricarbonyl unit needed for rapamycin. A model system was
constructed by first protecting the alcohol of 3-butyn-1-ol (142) with t-
butyldimethylsilyl chloride to give thesilylether 143 (Scheme XXI).
Formation of the lithium acetylide by treatment of 143 with n-butyllithium
followed by reaction with methyl chloroformate gave the acetylenic ester 14441
in excellent yield. However, when hydrolysis of 144 to the acetylenic acid 145
was attempted with lithium hydroxide or potassiumhydroxide,37 only
decomposition of the starting material resulted. Even under mild hydrolysis
conditions, for example with trimethylsilyl iodide in acetonitrile38 or with
aqueous sodium iodide and lutidine,39 decomposition of 144 wasstill the
principal result. Nevertheless, it was possible to oxidize the acetylenic ester
144 withcatalyticrutheniumtrichloride36ausingfreshlyprepared
iodosobenzene40 as the stoichiometric oxidant to give the a,(3-diketoester 146.
The latter was isolated as a hydrate, as was previously observed in a similar
tricarbonyl system,22c and was evident from both IR and NMR spectroscopy.
As a consequence of this favorable result, it was hoped that it would be
possible to construct an acetylene incorporating the requisite pipecolinic acid
moiety (Scheme XXII).First, the butynol 142 was treated with sodium hydride
in tetrahydrofuran and then with t-butyldiphenylsilyl chloride, to afford silyl
ether 147. When the acetylene was treated with zinc chloride and triethyl
orthoformate41 none of the desired diethyl acetal 148 was observed, but if 147
was initially deprotonated with lithium bis(trimethylsilyl)amideand then
reacted with triethyl orthoformate, a good yield of 148 was isolated.An
attempted hydrolysis of 148 using wet silica in dichloromethane gave no
observable aldehyde, but addition of a small amount of oxalic acid42 to the
wet silica converted 148 to the aldehyde 149 in excellent yield.Unfortunately,
all attempts to condense 149 with pipecolinic acid (128) to give 150 were
unsuccessful, decomposition of the starting materials being the predominant
outcome.HOB v
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With the failure to prepare a suitable alkyne precursor to the 1,2,3 -
tricarbonyl segment of rapamycin, a new approach was initiated which
envisioned raising the oxidation level of an a,(3- unsaturated ester to that of a
tricarbonyl system.This approach commenced from the benzyl ether of
methyl (S)-3-hydroxy-2-methylpropionate(132).The ester 133 was reduced44
with lithium aluminumhydride to give an alcohol which was converted to
its tosylate 151 with tosyl chloride in pyridine (Scheme XXIII). Displacement
of 151 with NaI gave the iodide 152 which underwent substitution of the
iodine with benzenesulfinic acid sodium salt35 to yield the sulfone 153.In a
separate sequence, epoxide 155 was obtained by reaction of (R)-glycidol (154)
with t-butyldimethylsilyl chloride and imidazole.
The sulfone 153 was converted to its anion with n-butyllithium in
hexamethylphosphoramide, and addition of the epoxide 155 to this solution
gave 156 in excellent yield. The sulfonyl group was cleaved from 156 with
sodium-mercury amalgam to afford the alcohol 157 (Scheme XXIV). The
secondary alcohol was protected as its t-butyldimethylsilyl ether and the
benzyl ether was cleaved by catalytic hydrogenation to produce the primary
alcohol158.Oxidation of 158 using freshly preparedDess-Martin
periodinane43 furnished the desired aldehyde 159. Wittig olefination of 159
withethyl(triphenyphosphoranylidene)acetategavethetransa,(3-
unsaturated ester 16044 in high yield, but all attempts at hydrolysis of this
ester to the carboxylic acid 161 were unsuccessful. This unexpected outcome
may have resulted from deprotonation of the 7-hydrogen of 160 to form a
relatively stable conjugated anion, a hypothesis which is supported by the
observed epimerization of 160.
As an alternative to the Wittig approach via 160, it was hoped45 that
aldehyde 159 could be coupled with the Wittig ylide 163 to give the
pipecolamide 165. Methyl (S)-N-chloroacetylpipecolate 131 was first treated
with sodium iodide to yield methyl (S)-N -iodoacetylpipecolate 162 (Scheme
XV). Reaction of 162 with triphenylphosphine gave the phosphonium salt
163, which was deprotonated with a stoichiometric amount of sodium
hydroxide44 to yield the stable phosphonium ylide 164 quantitatively.45
However, when coupling of aldehyde 159 and ylide 164 was attempted45, no
reaction was observed even under vigorous conditions, and the starting
aldehyde 159 was recovered unchanged.
0
1) LAH, 62%
MeO
133
OBn Ts0 OBn
2) TsCI, pyr, 65%
PhO2S OBn..,
153
0
HO
154
PhSO2Na, DMF
35°C, 79%
TBDMSCI, Imidazole,
CH2Cl2,79%
Scheme XXIII
151
Nal, acetone,
reflux, 68%
,......._,.....
I' ..'OBn
152
0f TBSO,
155PhO 2S OBn
153
TBSO.--. %%%%% OH
OTBS
158
1) n-BuLi, HMPA,
THF, -78
2) 0
TBS01-1
155
94%
SO2Ph
Me
46
TBSO %%%%OH OBn
1) TBDMSCI, 71%, (168)
2) H2, Pd/C, 70%
Dess-Martin periodinane,
83%
Ph3P =C H CO2Et,
TBSO, %%%%% 0 TBSO,.0
OTBS toluene, reflux,
156
Na(Hg), 40%
TBSO---%%" OHS OBn
157
159
93%
TBSO---0
Scheme XXIV
OTBS
CO2Et
160
1.5 N LION,
Me0H
OTBSC 02H
161131
CO2Me
CI
TBSO-._ ....
OTBS
159
Nal, 98%
NaOH,
100% from 162
164
162
PPh3
163
CO2Me
'Ph3 l-
Y---0.- TBSO--, ..... \
OTBS
ON
165
Me02C
47
Scheme XXV
As an alternative to the forgoing Wittig approach, it was surmised that
the tricarbonyl region of rapamycin could be obtained with bromoacetyl
pipecolate and aldehyde 159 using a Reformatski reaction46.Methyl
pipecolate (130) was treated with bromoacetylbromide to give the (S)-methyl
N -bromoacetylpipecolate (166), attempted coupling of the latter with aldehyde
159 in the presence of a zinc-copper couple failed to give the desired 13-48
hydroxyamide 167 (Scheme XXVI). With this failure, it was concluded that
none of the strategies investigated in the course of this research would
provide access to the tricarbonyl subunit of rapamycin.
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Chapter III. Conclusion
Much synthetic work has been directed by many research groups
towardsthesynthesisofthetricarbonylsubunitofthepotent
immunosuppressants rapamycin and FK506. Several different strategies have
been utilized by others to generate this tricarbonyl moiety.This project
demonstrated that ruthenium trichloride and iodosobenzene is able to carry
out oxidation of an alkyne to the hydrated tricarbonyl system 146 under mild
conditions, but extension of this approach to the corresponding segment of
rapamycin failed
Chan rearrangement of the pipecolinic acid containing derivative 135
was not successful.However, construction of the potential rapamycin
tricarbonyl subunit precursor 167 via coupling of sulfone 153 and the epoxide
155 was accomplished in good yield and resulted in the alcohol 156.This
alcohol was converted to the aldehyde 159 with Dess-Martin periodinane.
Unfortunately, all attempts to employ this aldehyde as a precursor to the
desired tricarbonyl system were unsuccessful.50
Chapter IV. Experimental
General Procedures.All anhydrous or air sensitive reactions were
carried out in flame dried glassware under inert (argon or nitrogen)
atmosphere. Stirring was accomplished with teflon coated magnetic stir bars.
Starting materials and reagents were purchased from commercial suppliers
and usually used without further purification. Tetrahydrofuran (TI-IF) and
diethyl ether were dried by distillation from potassium and benzophenone.
Dichloromethane (CH2C12), hexamethylphosphoramide (HlvIPA) and toluene
were distilled from calcium hydride.Ethyl acetate (EtOAc), hexanes, and any
other solvents used in reactions or for chromatographic purifications were
reagent grade and distilled prior to use through glass.
Concentration of products from solutions was accomplished by use of
a rotary evaporator under reduced pressure provided with a water aspirator,
unless otherwise specified. Residual solvents were removed by vacuum at
pressures less than 2 m m Hg. Syringes were oven dried at 160°C and cooled
to room temperature in a desiccator over anhydrous calcium sulfate.
Neutral silica gel (E. Merck, 230-400 mesh ATM) was used for flash
chromatography unless otherwise specified.All analytical thin layer
chromatography was conducted with 2.5 x 7 cm precoated aluminum E.
Merck TLC plates (0.2 mm of silica gel 60 F-254). Spots were visualized under
ultraviolet light (uv), exposure to iodine vapor, or by heating with a heat gun
after dipping or spraying with a 3% commercial solution of phosphomolybdic
acid in ethanol or a solution prepared from 1 g of vanillin in 15 mL of 0.1 M
H2SO4 and 85 mL of methanol.
Infrared (IR) spectra were measured with a Nicolet 5DXB FT-IR
spectrometer. Proton (1H NMR) and carbon (13C NMR) nuclear magnetic51
resonance (NMR) spectra were obtained with either a Bruker AM 400 or AC
300 spectrometer. All chemical shifts are reported in parts per million (ppm)
downfield from tetramethylsilane using the 8 scale. The 1H NMR spectral
data are reported in order of chemical shift, number of protons, multiplicity
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, and br=broad), and
coupling constant (J) in Hertz (Hz). Mass spectra (MS) were obtained using
ether a Varian MAT CH-7 or a Finnigan 4500 spectrometer at an ionization
potential of 70 eV. High resolution mass spectra were recorded using a Kratos
MS-50 TC spectrometer.
DL-N-Chloroacetyl-2-pipecolinic Acid (129).To a suspension of DL-
pipecolinic acid (434 mg, 2.66 mmol) in 10 mL of CH2C12 was added dropwise
a solution of chloroacetyl chloride (310 mg, 2.74 mmol) in 10 mL CH2C12 at
room temperature. The reaction was stirred for 18 min and quenched with 15
mL of water. To the mixture was added 300 mg of potassium carbonate and
the biphasic mixture was shaken. The layers were allowed to separate, and
the aqueous layer was washed with diethyl ether (2 x 30 mL) and the organic
layer was discarded. The aqueous layer was acidified to pH 2 with 1 N
hydrochloric acid and was extracted with Ethyl acetate (3 x 30 mL).The
combined organic extracts were dried over magnesium sulfate, filtered and
concentrated to give 487 mg (90%) of chloroacety1-2-pipecolinic acid: 1H NMR
(300 MHz, CDC13) 8 8.17 (2H, bs), 5.36 (1H, d, j=1.8 Hz), 4.71 and 4.59 (1H, ABX,
JAB=21, TAX=1 Hz), 4.21-4.07 (4H, m), 3.84 (1H, d, J=6 Hz), 3.34 (2H, td, J=4, 1
Hz), 2.32 (3H, d, J=5 Hz), 1.80-1.64 (4H, m), 1.64-1.30 (3H, m), 1.30-1.19 (2H, m),
0.88 (1H, m); 13C NMR (300 MHz, CDC13) 8 171.1, 166.4, 56.5, 52.3, 44.0, 41.1,52
26.3, 24.9, 20.6; IR (neat) 3200-3000 broad, 2951, 2361, 1736, 1617, 1455, 1208,
1169, 1142, 1026, 934, 898, 787, 725, 667 cm-1; HRMS calcd for C81-112C1NO3
205.05057 (M+). Found 205.1 (M+), 170.1, 160.0, 126.1, 84.1
Methyl DL-Pipecolate (130). To a solution of DL-pipecolinic acid (3.014 g,
23.30 mmol) in 70 mL of absolute methanol was added 8.0 mL of fuming
sulfuric acid dropwise at room temperature. The solution was heated to
reflux and stirred overnight. The cooled solution was neutralized topH7
with 3 M sodium hydroxide followed by addition of 25 g of potassium
carbonate. The resulting mixture was extracted with diethyl ether (3 x 50 mL).
The combined organic extracts were dried over magnesium sulfate, filtered
and concentrated by short path distillation.Further Kugelrohr distillation
gave 2.05 g (61.3%) of 130 as a clear oil: 1H NMR (300 MHz, CDC13) 8 3.72(3H,
s), 3.36(1H,dd,J=4, 1 Hz),3.09 (1H, d, J=4Hz),2.66 (1H, td, J=2, 0.6 Hz), 1.98
(1H,m), 1.81 (1H, m), 1.61-1.37 (4H, m), 1.26(1H,d, J=1 Hz), 0.88 (1H, m); 13C
NMR (300 MHz, CDC]3)8174.1,58.7, 51.9, 45.8, 29.3, 25.9, 24.1; IR (neat) 3353,
2936, 2855, 2789, 2365,1740,1439, 1358, 1331, 1257, 1204, 1127, 1053, 991, 902, 864,
756, 649 cm-1.
Methyl DL-N-Chloroacety1-2-pipecolate (131). From 129: To a stirred
solution of 129 (85.6 mg, 0.416 mmol) in 2 mL of diethyl ether was added
dropwise a 0.3 M solution of diazomethane in diethyl ether until a yellow
color persisted for 5 min. The solution was warmed gently to remove the
excess diazomethane. Removal of the residual ether by Kugelrohrdistillation
gave74.4mg (81%) of 131 as a clear oil.
From 130: To a solution of 130 (347 mg, 2.42 mmol) in 10 mL CH2C12
was added dropwise a solution of chloroacetyl chloride(279 mg, 2.47 mmol)53
in 4 mL of CH2C12 at room temperature. The solution was stirred for 10 min
and quenched with 10 mL water. The aqueous phase was adjusted to pH 2
with 1 N hydrochloric acid. Diethyl ether (50 mL) was added and the biphasic
mixture was shaken. The organic extract was washed with 15 mL of saturated
sodium bicarbonate and 15 mL of brine. The organic extract was dried over
magnesium sulfate, filtered and concentrated. The solvent was removed
under high vacuum to give 307 mg (58%) of 131 as a clear oil. 1H NMR (300
MHz, CDC13) 8 5.31 (2H, d, J=2 Hz), 4.57 (1H, ABX, TAB=18, TBx=4, TAx=0.6 Hz),
4.22-4.08 (6H, m), 3.81-3.67 (10H, m), 3.34 (2H, td, J=4, 1 Hz), 2.23 (3H, d, J=5 Hz),
1.77-1.62 (8H, m), 1.62-1.49 (2H, m), 1.49-1.26 (3H, m); 13C NMR (300 MHz,
CDC13) 8 171.1, 166.4, 56.5, 52.3, 44.0, 41.1, 26.9, 26.3, 24.9; IR (neat) 2951, 2862,
1744,1653, 1433, 1358, 1342, 1327,1283, 1242,1211, 1165, 1144, 1111, 1080, 1028,
997,955, 927, 870, 860, 821, 783,659 cm-1.HRMS calcd for C9H14C1NO3
219.06622 (M+). Found 219.1 (M+), 196.0, 184.1, 160.1, 142.1, 97.1, 84.1. For (S)-
(L)-N-chloroacetyl 2-methyl pipecolate [a]D = -67.7 (c=3.92, CHC13).
(2S)-Methyl 3-(Benzyloxy)-2-methylpropionate (133). To a solution of
(S)-(+)-methyl3-hydroxy-2-methylpropionate (2.65 g, 22.5 mmol) in 45 mL of
2:1 cyclohexane-CH2C12 was added 6.24 mL of benzyltrichloroacetimidate (33.8
mmol) and catalytic triflic acid. The solution was stirred at room temperature
for 24 h and then filtered to remove solids. The filtrate was washed with
saturated sodium bicarbonate and extracted with CI-12C12 (2 x 50 mL). The
combined organic extracts were dried over magnesium sulfate, filtered and
concentrated. The crude mixture was purified by column chromatography on
silica /hexane -EtOAc 4:1 to give 3.63 g (78%) of 133 as a pale oil. 1H NMR (300
MHz, CDC13) 8 7.35-7.20 (5H, m), 4.50 (2H, s), 3.50 (1H, dd, J=5.8 Hz and 5.8 Hz),
3.48 (1H, m), 2.78-2.73 (1H, m), 1.16 (3H, d, J=7.0 Hz). IR (neat) 3030, 2981, 2980,54
2948, 2902, 2863, 1739, 1494, 1456, 1366, 1250, 1202, 1098, 1024, 994, 740, 699, 606
cm-1.1H NMR and IR matched those from N. Reedy. LRMS calcd for
C12H1603 208.25 (Mt). Found 208 (Mt), 191, 177, 121, 107, 102, 91, 87, 77.
(2S)-3-(Benzyloxy)-2-methylpropionic Acid (134). To a stirred solution
of 133 (1.64 g, 7.86 mmol) in 50 mL of absolute methanol was add 1.5 N
lithium hydroxide (14.9 mL, 9.9 mmol) and the solution was stirred 24 h at
room temperature. The methanol was removed by roto-evaporation and the
basic aqueous layer was washed twice with CH2C12 (2 x 25 mL). The aqueous
layer was acidified to pH 2 with 1 N hydrochloric acid then extracted with
EtOAc (4 x 50 mL). The combined organic extracts were washed with brine,
dried over magnesium sulfate, filtered and concentrated to give 1.47 g (96%)
of 134 as a pale oil. 1H NMR (300 MHz, CDCI3) 8 11.3 (1H, bs), 7.35-7.20 (5H,
m), 4.55 (2H, s), 3.69-3.67 (2H, m), 2.80-2.75 (1H, m), 1.19 (3H, d, J=7 Hz); IR
(neat) 3500-3063 broad, 3063, 3031, 2980, 2939, 2905, 2867, 2668, 2654, 1709, 1458,
1421, 1365, 1291, 1251, 1228, 1097, 944, 914, 740, 699 cm-1. 1H NMR and IR
matched those from N. Reedy.
DL-Methyl N-12-(Benzyloxy)-(11S)-methylpropyloxoacety1-2-pipecolate
(135). To a solution of 131 (83.2 mg, 0.379 mmol) in 4 mL of dry acetone was
added 134 (74 mg, 0.38 mmol) in 4 mL dry acetone followed by addition of 150
mg potassium carbonate. The reaction mixture was heated to reflux for 4.5 h.
The cooled solution was filtered through florisil and diluted with diethyl
ether.The filtrate was dried over magnesium sulfate,filtered and
concentrated.The crude product was purified by flash column on
silica /hexane -EtOAc 1:1 to give 115 mg (80.6%) of 135 as a oil. 1H NMR (300
MHz, CDCI3) 8 7.34-7.23 (5H, m), 5.31 (2H, d, J=2 Hz), 4.92 (1H, dd, J=10, 5 Hz),55
4.62 (1H, dd, J=10, 5 Hz), 4.53 (2H, d, J=0.3 Hz), 4.13 (2H, dd, J=8, 6 Hz), 3.80-3.72
(6H, m), 3.58-3.52 (2H, dd, J--4, 2 Hz), 3.38-3.23 (1H, m), 2.96-2.88 (1H, m), 2.27
(21-1, m), 1.81-1.61 (4H, m), 1.57-1.31 (3H, m), 1.27 (3H, d, J=2 Hz);13C NMR
(300 MHz, CDC13) 8 174.2, 171.4, 166.6, 138.3, 128.4, 127.6, 73.2, 71.9, 61.4, 52.3,
44.2, 42.5, 41.2, 40.2, 40.1, 27.1, 26.5, 25.1, 25.0, 24.4, 20.8, 14.0; IR (neat) 3032,
2947, 2861, 2017, 1734, 1684, 1670, 1663, 1559, 1541, 1507, 1497, 1456, 1437, 1362,
1339, 1325, 1206, 1181, 1163, 1143, 1100, 1019, 742, 700 cm-1.
DL- N- Chloroacetyl- 2- piperdene Methanol (1381.To a solution of 2-
piperdine methanol (299 mg, 2.60 mmol) in 20 mL CH2C12 was added a
solution of chloroacetyl chloride (0.21 mL, 2.6 mmol) at room temperature.
The reaction was stirred for 25 min and quenched with saturated sodium
bicarbonate followed by extraction with ether (3 x 20 mL).The combined
organic extracts were washed with brine, dried over magnesium sulfate,
filtered and concentrated.Flash column on silica/ hexane- EtOAc -MeOH
4.5:4.5:1 gave 287 mg (58%) of 138 as a oil. 1H NMR (300 MHz, CDC13) 8 4.73
(1H, m), 4.39 (1H, ABX, JAB=11, JAX=4 Hz), 4.10 (3H, m), 3.84 (1H, t, J=3 Hz),
3.71 (1H, m), 2.05 (1H, s), 1.73-1.47 (10H, m), 1.31-1.26 (5H, m), .91-.83 (4H, m).
IR (neat) 3403-3390, 2941, 2870, 1716, 1634, 1447, 1375, 1361, 1324, 1280, 1255,
1171, 1140, 1121, 1052, 1028, 994, 788, 662 cm-1.
(S)-Methy N-( Isobutyrloxoacetyl- 2- pipecolate (141). To a solution of 132
(57 mg, 0.26 mmol) in 8 mL of acetone was added 150 mg potassium carbonate
and 0.024 mL isobutyric acid (0.26 mmol). The solution was warmed to reflux
for 4.5 h, then the cooled was filtered through florisil. The florisil was rinsed
with a small portion of ether and the combined filtrate was concentrated. The
crude mixture was purified by flash column on silica /hexane -EtOAc 1:1 to56
give 47 mg (67%) of 141 as a oil. [ar= -50.5;1H NMR (300 MHz, CDC13) 8
5.31 (1H, d, J=2 Hz), 4.81 (2H, dd, J=30, 5 Hz), 4.14 (0.3H, dd, J=10, 4 Hz), 3.76
(0.7H, d, J=4 Hz), 3.73 (1H, s), 3.65 (1H, d, J=16 Hz), 3.32 (1H, td, J=3, 4 Hz), 2.70
(1H, m), 2.28-1.27 (6H, m), 1.24 (6H, dd, J=2, 1 Hz), 1.05-.86 (1H, m); IR (neat)
3623-3613, 3474, 2947, 2866, 1750, 1734, 1679, 1448, 1384, 1354, 1327, 1249, 1209,
1192, 1159, 1149, 1098, 1017, 995, 950, 926, 901, 965, 824, 795, 779, 661 cm-1.
4-tert-Butyldimethylsilyloxy-1-butyne (143). To a solution of 3-butyn-l-
ol (1.19 g, 17.0 mmol) in 75 mL of dry THF under argon was added 3.8 g (34
mmol) of triethylamine followed by 3.8g (25 mmol) of tert-butyldimethylsilyl
chloride. The solution was stirred two days at room temperature.The
reaction was quenched with saturated sodium bicarbonate and extracted with
ether (2x40 mL). The combined extracts were washed with brine, dried over
magnesium sulfate,filteredandconcentrated.Flash column on
silica /hexane -EtOAc 95:5 gave 3.91g (95%) of 143 as a pale oil. 1H NMR (300
MHz, CDC13) 8 3.74 (2H, t, J=2 Hz), 2.39 (2H, td, J=2, 1 Hz), 1.96 (1H, t, J=1 Hz),
0.90 (9FI, s), 0.86 (6H, s);13C NMR (300 MHz, CDCI3) 8 77.1, 69.2, 61.6, 25.8,
22.8, 18.2, -5.4; IR (neat) 3316, 2956, 2930, 2885, 2858, 1734, 1472, 1464, 1362, 1256,
1107, 838, 778 cm-1. LRMS calcd for C10H200Si 184.1284 (M-1). Found 157, 145,
127, 109, 97, 73.
Methyl 5-tert-Butyldimethylsilyloxy-2-pentynoate (144). To a solution
of 143 (286 mg, 1.55 mmol) in 2 mL dry THF under argon was added 1.16 mL
(1.86 mmol) of 1.6 N n-butyllithium in hexanes at -78°C and the reaction was
stirred for 1 h. To the reaction was added 0.72 mL (9.3 mmol) of methyl
chloroformate and the reaction was stirred for 30 minutes then allowed to
warm to 0°C for 1 hour. The reaction was quenchedwith 7 mL of saturated57
sodium bicarbonate then diluted with ether. The phases were separated and
the aqueous was extracted with ether (3x25 mL).The combined organic
extracts were dried over magnesium sulfate, filtered and concentrated. Flash
column on silica /hexane -EtOAc 19:1 gave 334 mg (89%) of 144 as an oil. 1H
NMR (300 MHz, CDCI3) 8 3.78 (2H, t, J=2 Hz), 3.75 (3H, s), 2.55 (2H, t, J=2 Hz),
0.90 (9H, s), 0.08 (6H, s); IR (neat) 2955, 2933, 2860, 2243, 1720, 1468, 1437, 1412,
1388, 1256, 1112, 1078, 839, 779, 753 cm-1.
a,(3-Diketo Ester 146. To a solution of 144 (134 mg, 0.551 mmol) in 4.2
mL acetone was added freshly prepared iodosobenzene43 (369 mg, 1.65 mmol)
and 3 mg of RuC13.nH2O. The reaction was stirred 27 h, then concentrated.
Flash column on silica /hexane -EtOAc 1:1 gave 78.3 mg (51%) of 146 as a
hydrated oil. 1H NMR (300 MHz, CDCI3) 8 5.13 (2H, s, shifts to 4.71 with D20),
3.94 (2H, t, J=2 Hz), 3.85 (3H, s), 2.86 (2H, t, J=2. Hz), 0.88 (9H, s), 0.075 (6H, s);
13C NMR (300 MHz, CDC13) 8 202.0, 169.5, 92.8, 58.5, 53.7, 39.5, 25.8, 18.2, -5.6;
HRMS calcd for C12H2405Si 276.4053 (M+). Found 257, 229, 217, 187, 159, 145,
102, 89, 73; IR (neat) 3360 (broad), 2956, 2933, 2890, 2860, 1748, 1719, 1468, 1439,
1284, 1260, 1198, 1105, 940, 836 an-1.
tert-Butyldiphenylsilyl 3-Butynyl Ether (147). To a solution of 3-butyn-
1-01 (752 mg, 10.7 mmol) in 50 mL of THE was added 449 mg (11.2 mmol) of a
60% dispersion of sodium hydride in mineral oil at 0°C. The solution was
stirred 1 hour at 0°C then 2.10 mL (12 mmol) of tert-butyldiphenylsilyl
chloride was added. The reaction was warmed to room temperature and
stirred for 2 days.The reaction was quenched with saturated sodium
bicarbonate and extracted with ether (2x40 mL).The combined organic
extracts were washed with brine, dried over magnesium sulfate, filtered and58
concentrated. Flash column on silica /hexane -EtOAc 4:1 gave 1.808g (55%) of
147 as an oil. 11-1 NMR (300 MHz, CDCI3) 8 7.69-7.66 (5H, m), 7.43-7.38 (5H, m),
3.78 (2H, t, J=2 Hz), 2.45 (2H, td, J=2, 1 Hz), 1.94 (1H, t, J=1 Hz), 1.05 (9H, t, J=1
Hz); 13C NMR (300 MHz, CDC13) 8 135.5, 133.5, 129.6, 127.6, 81.4, 69.1, 62.0, 26.7,
22.5, 19.1, 16.0; IR (neat) 3306, 3071, 3050, 3019, 3000, 2883, 2850, 1590, 1469, 1445,
1427, 1388, 1221, 1111, 1080, 1033, 1005, 937, 829, 738, 705, 639, 615 cm-1.
5-(tert-Butyldimethylsilyloxy)pent-2-yne Diethyl Acetal (148).To a
solution of 147 (39 mg, 0.1 mmol) in 25 mL of dry ether at -78°C was added
0.13 mL (0.13 mmol) of 1 M lithium bis(trimethylsilyl)amide in THE under
argon. The solution was stirred for 5 minutes then warmed to 0°C for 30
minutes. To the reaction was added 0.022 mL (0.13 mmol) of freshly distilled
triethylorthoformate and thereaction was slowly warmed to room
temperature and stirred 8 hours. The reaction was quenched with saturated
sodium bicarbonate, extracted with ether (3x30 mL) and the combined organic
extracts were dried over magnesium sulfate, filtered and concentrated. Flash
column on silica /hexane -EtOAc 4:1 gave 39 mg (74%) of 148 as an oil.1H
NMR (300 MHz, CDCI3) 8 7.69-7.65 (5H, m), 7.42-7.35 (5H, m), 5.23 (1H, t, J=0.5
Hz), 3.8-3.67 (4H, m), 3.60-3.52 (2H, m), 2.51 (2H, td, J=3, 0.4 Hz), 1.21 (6H, t, J=2
Hz), 1.05 (9H, t, J=1 Hz); 13C NMR (300 MHz, CDC13) 8 135.5, 133.4, 133.1, 129.8,
129.6, 129.3, 127.7, 127.6, 91.3, 83.2, 62.0, 61.1, 60.5, 58.4, 27.4, 26.7, 23.2, 22.7, 19.1,
18.4, 15.9, 15.0, 3.3; IR (neat) 3071, 3050, 2959, 2933, 2885, 2860, 2205, 1670, 1470,
1428, 1388, 1361, 1331, 1151, 1110, 1054, 1007, 822, 738, 705, 613 cm-1.
5-tert-Butyldimethylsilyloxypent-2-ynal (149).To a suspension of silica
gel (70-230 mesh) in 2.5 mL of CH2C12 at room temperature was added 0.30 mL59
of 10 % aqueous oxalic acid solution. The suspension was stirred for 2 min.
To the suspension was added 98 mg (0.24 mmol) of 148 in 0.5 mL of CH2C12.
The reaction mixture was stirred for 4.5 h then 100 mg of solid sodium
bicarbonate was added. The mixture was stirred for an additional 10 min then
filtered.The solids were washed repeatedly with ethyl acetate and finally
with a small (8 mL) portion of methanol. The combined organic filtrate was
driedover magnesiumsulfate,filteredandconcentrated. Plate
(chromatatron) chromatography with pentane-ether 9:1 gave 75 mg (93%) of
149 as an oil. 1H NMR (300 MHz, CDC13) 8 9.14 (1H, d, J=0.3 Hz), 7.69-7.65 (5H,
m), 7.44-7.36 (5H, m), 3.83 (2H, t, J=2 Hz), 2.65 (2H, t, J=2 Hz), 1.06 (9H, t, J=1
Hz); 13C NMR (300 MHz, CDC13) 8 176.9, 135.5, 133.1, 129.8, 127.7, 96.1, 88.3,
61.1, 26.7, 23.2, 19.1, 15.9, 3.3; IR (neat) 3071, 3050, 3020, 2999, 2957, 2933, 2858,
2280, 2205, 1669, 1468, 1428, 1387, 1137, 1110, 823, 738, 704, 614 cm-1.
(2R)-3-(Benzyloxy)-2-methylpropanol. To a solution of 133 (5.29 g, 20.4
mmol) in 20 mL of dry ether under argon at 0°C was added a suspension of
lithium aluminum hydride (773 mg, 20.4 mmol) in 50 mL of ether over 30
min. The reaction was warmed to room temperature and stirred for 30 min.
The reaction was quenched with 2 mL of saturated sodium bicarbonate then 4
mL of water. The slurry was stirred for 15 min. Magnesium sulfate was
added, and the resulting solids were filtered and washed with 200 mL of ether.
The filtrate was concentrated and flash column on silica /hexane -EtOAc 2:1
gave 2.34 g (64%) of (2R)-3-(benzyloxy)-2-methylpropanol as a clear oil.1H
NMR (300 MHz, CDCI3) 8 7.33 (5H, m), 4.52 (2H, s), 3.62 (2H, m), 3.55 (1H, t, J=2
Hz), 3.43 (1H, t, J=3 Hz), 2.50 (1H, b), 2.09 (1H, m), 0.88 (3H, d, J=2 Hz); 13C
NMR (300 MHz, CDCI3) 8 137.9, 128.4, 127.6, 127.5, 73.3, 67.7, 35.5, 13.4;IR60
(neat) 3409 (broad), 3109, 3030, 2959, 2923, 2870, 1492, 1455, 1364, 1257, 1209,
1096, 1038, 994, 739, 699, 605 cm-1. FIRMS calcd for C11I-11602 180.1151 (Mt).
Found 180 (Mt), 165, 107, 91, 79.
(2S)-1-(Benzyloxy)-2-methyl -3-(p-toluenesulfonyloxy)propane (151). To
a solution of (2R)-3-(benzyloxy)-2-methylpropanol (2.34 g, 13.0 mmol) in 50
mL of pyridine was added p - toluenesulfonyl chloride (3.34 g, 17.6 mmol). The
reaction was stirred for 2 days at room temperature. The reaction solution
was poured into 10 N hydrochloric acid and ice.The aqueous layer was
extracted with ether (3x50 mL). The combined extracts were washed with
water, saturated copper sulfate, and brine.The combined extracts were dried
over magnesium sulfate, filtered and concentrated.Flash column on
silica /hexane -EtOAc 3:1 gave 2.88 g (66%) of 151 as an oil. Car= +4.8 (c=2.5,
CHC13); 1H NMR (300 MHz, CDC13) 8 7.92 (2H, d, J=1 Hz), 7.30 (7H, m), 4.40
(2H, s), 4.02 (2H, m), 3.33 (2H, m), 2.42 (3H, s), 2.10 (1H, m), 0.94 (31I, d, J=2 Hz);
13C NMR (300 MHz, CDCI3) 8 144.5,138.1, 132.9, 129.7, 128.2, 127.8, 127.5, 127.3,
73.0, 72.1, 71.0, 33.6, 21.5, 13.5, 4.6; IR (neat) 2968, 2925, 2862, 1456, 1361, 1181,
1098, 975, 944, 836, 816, 741, 698, 667 cm-1; LRMS calcd for C18E12204,5 454.45
(Mt). Found 334, 173, 155, 107, 91.
(2S)- 1- (Benzyloxy) -2- methyl -3- iodopropane (152).To a solution of 151
(2.88 g, 8.60 mmol) in 20 mL of acetone was added 2.58 g (17.2 mmol) of
sodium iodide.The solution was heated to reflux for 4 h.The cooled
reaction was poured into 25 mL of water. The mixture was extracted with 100
mL of ether.The ether extract was washed with saturated sodium
bicarbonate, saturated sodium thiosulfate, and brine. The extract was dried
over magnesium sulfate, filtered and concentrated.Flash column on61
silica /hexane -EtOAc 6:1 gave 1.91 g (77%) of 152 as a colorless oil.[a]o=
+9.95 (c=3.67, CHC.13); 1H NMR (300 MHz, CDC13) 8 7.73 (5H, m), 4.5 (2H, s),
3.32 (4H, m), 1.81 (1H, m), 0.99 (3H, d, J=2 Hz); 13C NMR (300 MHz, CDC13) 8
138.2, 128.7, 128.3, 127.5, 74.0, 73.1, 35.1, 17.6, 13.9; IR (neat) 3062, 3028, 2962,
2927, 2859, 1494, 1454, 1424, 1365, 1326, 1250, 1200, 1100, 1027, 739, 698, 605 cm-1;
LRMS calcd for CiiHnOI 290.14 (14÷). Found 270, 180, 107, 91, 71.
(2S)-1-(Benzyloxy)-2-methylpropyl Phenylsulfone (153). To a solution
of 152 (1.70 g, 5.86 mmol) in 15 mL dimethylformamide was added benzene
sulfinic acid sodium salt (1.44 g, 8.79 mmol) and the reaction was warmed to
35°C overnight. The reaction was poured into saturated sodium bicarbonate
and extracted with ether. The organic extract was washed with brine, dried
over magnesium sulfate, filtered and concentrated.Flash column on
silica /hexane -EtOAc 4:1 gave 79% of 153 as an oil. [at:. +4.2 (c =2.1, CHC13);
1H NMR (300 MHz, CDC13) 8 7.91 (2H, m), 7.63 (3H, m), 7.33 (5H, m), 4.41 (2H,
d, J=1 Hz), 3.40 (2H, m), 3.38 (1H, q, J=1 Hz), 2.93 (1H, cF J=3 Hz), 2.38 (1H, m),
1.11 (3H, d, J=2 Hz); 13C NMR (300 MHz, CDC13) 8 140.0, 138.0, 133.4, 129.1,
128.2, 127.7, 127.5, 127.4, 73.5, 72.8, 59.2, 29.3, 17.1; IR (neat) 3064, 3030, 2967,
2927, 2862, 1451, 1361, 1306, 1148,1086, 743, 694 cm-1.
(2R)-1-tert-Butyldimethylsilyloxy-2-propyleneOxide(155).Toa
solution of (R)-glycidol (50 mg, 0.67 mmol) in 2 mL dry CI-12C12 under argon
was added imidazol (64 mg, 0.95 mmol) and 111 mg of tert-butyldimethylsilyl
chloride (0.74 mmol). The reaction was stirred at room temperature for 3 days
then poured into saturated sodium carbonate.The aqueous layer was
extracted with CH2C12 and the extract was washed with brine. The extract was
dried over magnesium sulfate, filtered and concentrated. Flash column on62
silica/pentane-ether 6:1 followed by vacuum distillation gave 63.5 mg of 155
as a colorless oil.[a]D= +2.35 (c=3.1, CHC13); 1H NMR (300 MHz, CDC13) 8
3.82 (1H, m), 3.70 (2H, m), 3.58 (2H, m), 0.95 (6H, s), 0.89 (9H, s); 13C NMR (300
MHz, CDCI3) 8 71.3, 63.3, 45.2, 25.7, -5.6; IR (neat) 2956, 2932, 2894, 2860, 1467,
1255, 1132, 1098, 840, 778 cm-1.
(2S,5S )-6-Benzyloxy-2-hydroxy-5-methyl-4-(phenylsulfonyl)hexyltert-
Butyldimethylsilyl Ether (156). To a solution of the 153 (300 mg, 0.990 mmol)
in 3 mL of THF at -78°C under argon was added 0.63 mL of n -butyllithium
(1.0 mmol) in hexanes. The reaction was stirred for 20 min then 0.21 mL of
hexamethylphosphoramide (1.2 mmol) in 2 mL of THF was added to the
reaction. The reaction was stirred for 10 min then 131 mg (0.70 mmol) of 155
in 2 mL THF was added. The reaction was warmed to 0°C and stirred 2.25 h.
The reaction was quenched with saturated ammonium chloride and extracted
with ether (2x50 mL). The organic layers were washed with brine, dried over
magnesium sulfate,filteredandconcentrated.Flash column on
silica /hexane -EtOAc 4:1 gave 326 mg (94%) of 156 as a oil. 1H NMR (300 MHz,
CDCI3) 8 7.90 (2H, m), 7.57 (3H, m), 7.33 (5H, m), 4.41 (2H, dd, J=5, 6 Hz), 4.13
(0.51-1, q, J=2 Hz), 3.64 (1H, td, J=2, 0.5 Hz), 3.39 (2H, m), 3.33 (2H, m), 2.93 (0.5H,
q, J=2 Hz), 2.64 (1H, m), 2.37 (1H, m), 2.04 (1H, s), 1.81 (0.5H, m), 1.26 (0.5H, t,
J=2 Hz), 1.13 (2H, dd, J=1, 1 Hz), 1.01 (1H, d, J=4 Hz), 0.87 (9H, d, J=2 Hz), 0.04
(6H, t, J=2 Hz); 13C NMR (300 MHz, CDC13) 8 140.1, 138.1, 133.5, 129.2, 129.2,
128.9, 128.7, 128.5, 128.4, 127.8, 127.6, 127.5, 127.5, 127.2, 127.2, 73.5, 72.9, 70.6,
59.2, 43.4, 29.4, 25.8, 25.6, 19.7, 17.2, 6.1; IR (neat) 3505 (broad), 2955, 2930, 2883,
2858, 1451, 1363, 1306, 1256, 1146, 1087, 840,779,740,695 cm-1;LRMS calcd for
C26H4005SSi 492.75 (W). Found 493 (W),475,435,419, 385,327, 305, 271, 197,
181, 143, 118, 107, 91.63
(2S,5S)-6-Benzyloxy-2-hydroxy-5-methylhexyltert-Butyldimethylsilyl
Ether (157).To a solution of 156 (727 mg, 1.48 mmol) in 35 mL absolute
ethanol was added 27.3 g of 2.5 % Na/Hg amalgam (2.97 mmol). The reaction
was stirred overnight at room temperature then quenched with saturated
NH4C1. The mixture was extracted with ether (3 x 100 mL). The combined
extracts were dried over magnesium sulfate, filtered and concentrated. Flash
column on silica/hexane-Et0Ac 4:1 gave 246 mg (47%) of 157 as a oil.[arD=
+4.1 (c=1.4, CHC13); 1H NMR (300 MHz, CDCb) 8 7.32 (5H, m), 4.49 (2H, s), 3.61
(211, m), 3.33 (2H, m), 2.4 (1H, bs), 1.77 (1H, m), 1.61 (1H, m), 1.46 (2H, m), 1.15
(1H, m), 0.94 (3H, d, J=2 Hz), 0.90 (9H, s), 0.07 (6H, s);13C NMR (300 MHz,
CDCI3) 8 138.8, 128.7, 128.2, 127.4, 127.3, 75.8, 73.3, 72.9, 67.2, 33.6, 31.6, 29.0, 25.9,
18.3, 17.4, -4.3, -4.8, -5.3; IR (neat) 3458 (broad), 2954, 2930, 2858, 1458, 1255, 1101,
838, 778, 736, 698 cm-1; LRMS calcd for C20H3603Si 352.59 (M+). Found 352
(M+), 187, 131, 117, 105, 91, 75.
(2S,5S)-5,6-Di(tert-butyldimethylsilyloxy)-2-methylhexan-1 -ol (159). To
asolutionof(2S,5S)-1-benzyloxy-5,6-di(tert-butyldimethylsiloxy)-2-
methylhexane (303 mg, 0.649 mmol) in 5 mL of ethyl acetate was added 50 mg
of 10 % Pd/C then 5 pL of 10% hydrochloric acid. The reaction was stirred for
12 hours under hydrogen at room temperature then 20 pL of triethylamine
was added followed by the magnesium sulfate.The mixture was filtered
through celite and washed with 30 mL of ethyl acetate.The filtrate was
concentrated. Flash column on silica /hexanes -EtOAc 4:1 gave 215 mg (88%)
of 159 as an oil. {at = -8.25 (c=1.2, CHC13); 1H NMR (300 MHz, CDC13) 8 3.65
(1H, m), 3.51 (2H, dd, J=2, 6 Hz), 3.43 (2H, m), 1-65-1.35 (6H, m), 0.93 (3H, d, J=264
Hz), 0.89 (9H, s), 0.88 (9H, s), 0.06 (6H, s), 0.05 (6H, d, J=1 Hz); 13C NMR (300
MHz, CDC13) 8 76.2, 68.1, 67.1, 35.8, 31.4, 28.2, 25.9, 25.8,18.1, 16.6, 5.3, -4.46, -4.8,
-5.4.
(2S,5S)-5,6-Di(tert-butyldimethylsilyloxy)-2-methylhexanal (160).To a
solution of 159 (110 mg, 0.268 mmol) in 10 mL CH2C12 was added 190 mg (0.43
mmol) of Dess-Martin periodinane.The reaction was stirred at room
temperature for 45 min then poured into 45 mL of saturated sodium
bicarbonate. The mixture was diluted with 75 mL of ether and 3g of Na2S203
the was added to the biphasic mixture. The phases were shaken together and
allowed to separate. The organic phase was washed with 20 mL of saturated
sodium bicarbonate then 20 mL of brine. The organic phase was dried over
magnesiumsulfate,filteredandconcentrated.Flash column on
silica /hexane -EtOAc 4:1 gave 91 mg (83%) of 160 as an oil. 1H NMR (300 MHz,
CDC13) 8 9.61 (1H, s), 3.66 (1H, m), 3.52 (1H, m), 2.34 (1H, m), 1.42 (2H, m), 1.25
(2H, m), 1.09 (3H, d, J=2 Hz), 0.92 (9H, d, J=1 Hz), 0.88 (9H, d, J=0.4 Hz), 0.58
(12H, m); 13C NMR (300 MHz, CDC13) 8 205.2, 72.8, 67.0, 46.4, 31.5, 25.9, 23.1,
18.3, 12.3, 6.0, -4.3, -4.8, -5.3; IR (neat) 2956, 2932, 2899, 2889, 2859, 2805, 2709,
1730, 1467, 1389, 1363, 1254, 1216, 1189, 1114, 1069, 1005, 983, 939, 920, 835, 813,
777, 721, 666 cm-1.
(S)-Methyl N-Iodoacetylpipecolate (163). To a solution of 131 (115 mg,
0.576 mmol) in 3 mL of acetone was added 86 mg (0.58 mmol) of sodium
iodide.The reaction was stirred overnight at room temperature.The
reaction was treated with 20 mL of water to dissolve solid sodium chloride
and the resulting mixture was extracted with ether (3 x 30 mL). The combined
extracts were washed with saturated Na2S203 and then brine. The combined65
extracts were dried over magnesium sulfate, filtered and concentrated. Plate
chromatography on silica/Et0Ac gave 162 mg (98%) of 163 as a pale yellow oil.
[a]2,1= -31.3 (c=1.42, CHCI3); 1H NMR (300 MHz, CDC13) 8 5.33 (0.7H, d,J=2
Hz), 4.55 (0.3H, m), 3.78 (21-1, m), 3.74 (3H, s), 3.26 (1H, dt, J=2, 5 Hz), 2.24 (1H, d,
J=4 Hz), 1.72 (5H, m), 1.37 (1H, m); 13C NMR (300 MHz, CDC13) 8 171.5, 167.8,
57.48,52.2,45.15,39.91, 26.36, 24.71, 20.63, -3.96; IR (neat) 2945, 2860, 1739, 1643,
1441,1415,1341,1275, 1210, 1164, 1144, 1021 cm-1; LRMS calcd for C9H1403IN
311.12 (M+). Found 312 (M+), 280, 252, 184, 154, 144, 89.66
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